Terns Pharmaceuticals, Inc. announced that Senthil Sundaram has resigned from his position as Terns' Chief Executive Officer for health reasons previously disclosed in January 2022. Mr. Sundaram also resigned from the Board of Directors of Terns but will remain on as a Senior Advisor to the Company. Erin Quirk, M.D., President and Head of Research & Development at Terns, will assume leadership of the Company, effective immediately.

Dr. Quirk has served as Terns' President since June 2020 and as Head of Research & Development since May 2021. She joined Terns as Chief Medical Officer in 2019.